Last updated: February 14, 2025
Sponsor: University of Alabama at Birmingham
Overall Status: Active - Recruiting
Phase
N/A
Condition
Sickle Cell Disease
Red Blood Cell Disorders
Treatment
Plant-based omega-3-FA
Clinical Study ID
NCT05758766
IRB-300010261
K23HL173704
Ages 5-18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Diagnosis of sickle cell anemia HbSS or HbSB0 thal at steady state
Age 5-18 years old
Exclusion
Exclusion Criteria:
Age less than 5 years
Age > 18 years old
Chronic transfusion therapy
Known to be pregnant
Breastfeeding mothers
Current use of antibiotics
Use of pre or probiotic supplements
PPI therapy
Known allergy to FS
Study Design
Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Plant-based omega-3-FA
Phase:
Study Start date:
August 30, 2023
Estimated Completion Date:
December 30, 2026
Study Description
Connect with a study center
University of Alabama at Birmingham
Birmingham, Alabama 35233
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.